Skip to content
Pharmaids Pharmaceuticals logo

Pharmaids Pharmaceuticals

524572 BSE
Price unavailable

Pharmaids Pharmaceuticals (PHARMAID) share price was ₹27.52 at the 28 Oct 2026 close; market capitalisation ₹97.04 Cr; sector Healthcare. The share price fell 45.8% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue fell 38.1% year on year to ₹4.12 Cr and net profit was ₹1.88 Cr, against −₹5.27 Cr a year earlier (compared with Jun 2025). Promoters held 32.99% of Pharmaids Pharmaceuticals in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 47/100 (Average) as of 28 Oct 2026.

Close 28 Oct 2026 ₹27.52 −23.46 −46.02% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹97.04 Cr
EBITDA
−₹13.20 Cr
Return on Equity
-24.31%
Debt to Equity
0.49
Book Value
₹13.51
EPS (TTM)
−₹1.29
52W High
₹53.90
52W Low
₹25.60

Price-based figures as of 28 Oct 2026, 15:30 IST · EPS basis: Consolidated · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,765.8035.034,23,675 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,653.0087.612,56,257 Cr15.290.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,606.6072.321,75,220 Cr9.540.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,186.60108.031,18,145 Cr22.290.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,181.3026.291,17,835 Cr4.350.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,338.8034.671,11,747 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,364.7032.701,10,248 Cr3.110.96%11.21%14.88%28,589 Cr3,356 Cr
Pharmaids Pharmaceuticals (this company)
——97 Cr2.040.00%-24.31%-20.25%33 Cr-4 Cr
Median 8 companies₹1,765.8035.031,17,990 Cr4.710.47%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

47 Average
Overall score

Data confidence 88/100

Category scores

Quality Weak 44
Returns, margins, earnings quality 22% weight
Valuation Good 58
Cheap vs sector & own history 24% weight
Growth Good 64
Sales & profit trajectory 9% weight
Financial Health Poor 17
Solvency, leverage, coverage 9% weight
Momentum Poor 33
Trend strength, vol-adjusted 12% weight
Ownership Average 50
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company has reduced debt.
  • Debtor days have improved from 56.1 to 44.9 days.

Weaknesses

3
  • Company has low interest coverage ratio.
  • Promoter holding is low: 33.0%
  • Company has a low return on equity of -19.4% over last 3 years.

Technical Indicators

Oscillators

Neutral

Bearish
2
Neutral
5
Bullish
2

Overall

Bearish

Bearish
12
Neutral
5
Bullish
2

Moving Averages

Bearish

Bearish
10
Neutral
0
Bullish
0

Growth Rate

Revenue Growth
43.88% higher than 3Y

change over 1 year

Net Income Growth
-14.07% higher than 3Y

change over 1 year

Cash Flow Change
73.13%

change over 1 year

EBITDA Margin Change
-27.33%

change over 1 year Operating margin -18.2% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
0
0
0.02
5.81
4.73
5.24
4.71
4.77
6.66
8.61
5.43
7.18
4.12
Expenses
1.61
1.02
2.45
11.39
8.14
7.65
7.6
8.67
12.03
13.93
7.94
7.52
4.87
Operating Profit
-1.61
-1.02
-2.43
-5.58
-3.41
-2.41
-2.89
-3.9
-5.37
-5.32
-2.51
-0.34
-0.75
OPM %
—
—
-12150%
-96.04%
-72.09%
-45.99%
-61.36%
-81.76%
-80.63%
-61.79%
-46.22%
-4.74%
-18.2%
Other Income
0.41
-0.26
0.76
0.12
-0.07
0.08
0
0.13
0.04
3.03
-0.32
0.01
4.25
Interest
0
0
0.02
0.77
0.26
0.33
0.48
1.01
1.2
0.93
0.72
0.65
0.6
Depreciation
0.01
0.01
0.04
0.63
0.57
0.61
0.64
0.62
0.61
0.47
0.48
0.48
0.49
PBT
-1.21
-1.29
-1.73
-6.86
-4.31
-3.27
-4.01
-5.4
-7.14
-3.69
-4.03
-1.46
2.41
Tax %
7.44%
-60.47%
-33.53%
-7.73%
-27.38%
-30.58%
-24.94%
-11.11%
-26.05%
-30.62%
-34.24%
-25.34%
22.41%
Net Profit
-1.3
-0.5
-1.15
-6.33
-3.12
-2.27
-3.01
-4.8
-5.27
-2.57
-2.65
-1.09
1.88
EPS (₹)
-0.61
-0.23
-0.54
-1.57
-0.76
-0.55
-0.55
-1.12
-1.39
-0.71
-0.7
-0.51
0.63
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
3.94
0
15.11
19.45
27.88
25.34
Expenses
3.81
9.89
27.46
32.2
41.39
34.26
Operating Profit
0.13
-9.89
-12.35
-12.75
-13.51
-8.92
OPM %
3.3%
—
-81.73%
-65.55%
-48.46%
-35.2%
Other Income
0.02
0
0.03
0.01
2.75
6.97
Interest
0
0
1.58
2.1
3.52
2.9
Depreciation
0.01
0.02
1.72
2.44
2.03
1.92
PBT
0.14
-9.91
-15.62
-17.28
-16.31
-6.77
Tax %
0%
-23.71%
-24.2%
-21.88%
-29%
—
Net Profit
0.15
-7.56
-11.85
-13.51
-11.57
-4.43
EPS (₹)
0.15
-3.52
-2.26
-3.06
-3.32
-1.29
Div. Payout %
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
10.27
21.44
35.27
35.27
35.27
Reserves
-1.6
1.02
36.78
24.05
12.39
Borrowings
0
0
8.53
38.98
23.39
Other Liabilities
2.44
2.13
10.75
21.54
16.21
Total Liabilities
11.11
24.59
91.33
120
87.26
Fixed Assets
0.03
0.11
63.42
76.61
53.94
CWIP
0.45
2
7
4.53
6.1
Investments
0
3.31
0
0
0
Other Assets
10.63
19.17
20.91
38.7
27.22
Total Assets
11.11
24.59
91.33
120
87.26
Figures in ₹ Crores

Cash Flow

Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
-0.26
-4.02
-10.62
-15.11
-4.06
Investing
0.47
-4.94
-74.99
-12.22
23.34
Financing
0
21.31
77.66
23.36
-19.97
Net Cash Flow
0.21
12.35
-7.95
-3.98
-0.69
Free Cash Flow
-0.26
-5.69
-33.33
-27.37
11.05
CFO/OP
-200
41
86
118
30
Figures in ₹ Crores

Ratios

Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
124
—
64.74
58.74
44.9
Inventory Days
90.99
—
112
347
8.73
Days Payable
236
—
159
464
59.17
Cash Conversion Cycle
-21.05
—
17.17
-59.04
-5.54
Working Capital Days
-17.6
—
-68.6
-160
-172
ROCE %
—
-63.67%
-25.99%
-17.43%
-18.48%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Pharmaids Pharmaceuticals insights

63 extracted metrics + investor summaries across FY11–FY27.

Shareholding Pattern

Public47.49%Others19.52%Promot.32.99%As ofSep 2026

Documents

Frequently Asked Questions about Pharmaids Pharmaceuticals

What does Pharmaids Pharmaceuticals Ltd do?
Incorporated in 1989, Pharmaids Pharmaceuticals Ltd operates in research, development, and manufacturing services. It is undergoing a business transition and aims to build a CRDMO platform.[1]
Where is Pharmaids Pharmaceuticals Ltd (PHARMAID) listed?
Pharmaids Pharmaceuticals Ltd trades under code 524572 on the BSE.
Which sector does Pharmaids Pharmaceuticals Ltd belong to?
Pharmaids Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Pharmaids Pharmaceuticals Ltd?
Pharmaids Pharmaceuticals Ltd has a market capitalisation of ₹97.04 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the 52-week high and low of Pharmaids Pharmaceuticals Ltd?
Over the last 52 weeks Pharmaids Pharmaceuticals Ltd has traded between ₹25.6 and ₹53.9 as of 28 Oct 2026.
What is the Return on Equity (ROE) of Pharmaids Pharmaceuticals Ltd?
Pharmaids Pharmaceuticals Ltd reported a return on equity of -24.31%. Its debt-to-equity ratio is 0.49.

Company Information

Incorporated in 1989, Pharmaids Pharmaceuticals Ltd operates in research, development, and manufacturing services. It is undergoing a business transition and aims to build a CRDMO platform.[1]

Website pharmaids.com
Face Value ₹ 10
Shares Outstanding 3,52,61,897

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524572.md for Pharmaids Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month